The first patient dosed in Australia with INNOGEN-B(02591) in a Phase II clinical trial for the treatment of obesity and overweight with exenatide alpha was completed.
Silver Noble Pharmaceuticals-B (02591) announces that on August 25, 2025, the company has completed the acquisition in Australia...
INNOGEN-B (02591) announces that on August 25, 2025, the company has dosed the first patient in Australia with IISupageglutide-alpha for the treatment of obesity and overweight in a phase II clinical trial. The company anticipates that approximately 200 participants will be enrolled in this clinical trial.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
